Seamus Mulligan - 28 May 2026 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Reporting relationship: Director
Issuer ticker: JAZZ
Reported as of: 28 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 16:01:41 UTC
Prior SEC filing: 11 Aug 2025
Source filing: View source filing
Reporting owner signature: By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan

Key filing fact

Seamus Mulligan filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 01 Jun 2026.

Key facts

This page summarizes Seamus Mulligan's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Jun 2026, 16:01.

Change

Previous filing in this sequence was filed on 11 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536639 Primary reporting owner

Mulligan Seamus

Relationship: Director
Address: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND
Signature: By: /s/Paz Dizon, as attorney in fact For: Seamus Mulligan
Signature date: 01 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JAZZ transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +3,415
Change %: +0.29%
Price: $138.08^*
Shares after: 1,183,028
Date: 28 May 2026
Ownership: Direct

JAZZ holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 101,621
Date: 28 May 2026
Ownership: By Nerano Pharma Lim
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JAZZ transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -3,415
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 May 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 3,415
Exercise price: $138.08
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.

Footnote F2

This non-qualified stock option was granted on August 11, 2016 and vested over the period from September 1, 2016 through August 1, 2017. The options were fully vested as of August 1, 2017.